E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
insulin-dependent autoimmune diabetes |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Hormonal diseases [C19] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the degree of insulin dose reduction 24 hours after a single dose of 10mg dapagliflozin in patients with type 1 diabetes
|
|
E.2.2 | Secondary objectives of the trial |
To investigate the effect on urinary glucose excretion
To investigate if this effect is influenced by baseline glycemic control
To investigate if dapagliflozin influences postprandial insulin need
To investigate if dapagliflozin is associated with elevated ß-hydroxybutyrate levels
To investigate PK after oral administration of 10mg dapagliflozin
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
For inclusion in the study subjects should fulfill the following criteria:
1. Provision of informed consent from participant and all legal representatives prior to any study specific procedures
2. Female and/or male aged 12 to 21years (both inclusive)
3. Subject must have type 1 diabetes (as diagnosed clinically) ≥ 12 months
4. without completely inadequate glycemic control, defined as local laboratory A1c above 12.5% (subjects will be stratified according to glycemic control being in target (A1c 5.5 to 7.4%), slightly elevated (7.5 – 9.0%) or clearly elevated 9.1 – 12.5% ) obtained at the screening visit (Note: A one-time central laboratory re-test of the A1C is allowed)
5. Insulin use with an average daily dose between 0.6 – 2.0 U/kg, either continuous subcutaneous insulin infusion, (CSII) or multiple doses (at least 2x/day) of insulin
6. BMI 18.0 to 35.0 kg/m2 for adults or BMI between 10th and 99th age and gender related centile for pediatric patients
7. Minimum weight of 50 kg
8. Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy throughout the study as judged by the investigator
9. WOCBP must have a negative urine pregnancy test at screening as well as at Visit 2 and Visit 4.
10. Women must not be breastfeeding
|
|
E.4 | Principal exclusion criteria |
1) Target Disease Exclusions
a) History of T2DM, maturity onset diabetes of young (MODY), pancreatic surgery or chronic pancreatitis
b) Any use of oral hypoglycemic agents within 12 months prior to the screening visit
c) History of diabetes ketoacidosis (DKA) within 12 weeks prior to prior to the screening visit
d) History of diabetes insipidus
e) History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia)
within 3 months prior to prior to the screening visit
f) Frequent episodes of hypoglycemia as defined by more than one episode requiring assistance, emergency care (paramedics or emergency room care) or glucagon therapy, or more than 2 unexplained episodes of symptomatic hypoglycemia within 3 months prior to the screening visit. An unexplained event is defined as an event that cannot be explained by circumstances such as dietary (e.g. missed meal), strenuous exercise, error in insulin dosing, etc.
g) Hypoglycemic unawareness
h) History of Addison’s disease or chronic adrenal insufficiency
2) Physical and Laboratory Test Findings
a) Aspartate aminotransferase (AST) > 2X Upper limit of normal (ULN)
b) Alanine aminotransferase (ALT) > 2X ULN
c) Serum total bilirubin > 2X ULN
d) Estimated GFR (eGFR) by the Modification of Diet in Renal Disease (MDRD) formula ≤ 60 ml/min/1.73m2. e) Hemoglobin ≤ 11.0 g/dl (110 g/l) for boys / men; hemoglobin ≤10.0 g/dl (100 g/L) for girls / women.
f) Creatine kinase (CK) > 3X ULN
g) Positive for hepatitis B surface antigen or anti-hepatitis C virus antibody.
h) Abnormal Free T4
3) Allergies and Adverse Drug Reaction
a) Allergies or contraindication to the contents of dapagliflozin tablets or insulin
4) Renal, Hepatic, Hemotological/Oncological Diseases/Conditions
a) History of unstable or rapidly progressing renal disease
b) Conditions of congenital renal glucosuria
c) Renal allograft
d) Significant hepatic disease, including but not limited to, chronic active hepatitis and/or severe hepatic insufficiency
e) Documented history of hepatotoxicity with any medication
f) Documented history of severe hepatobiliary disease
g) History of hemoglobinopathy, with the exception of sickle cell trait (SA) or thalassemia minor; or chronic or recurrent hemolysis
h) Donation of blood or blood products to a blood bank, blood transfusion, or participation in a clinical study requiring withdrawal of > 400 mL of blood during the 6 weeks prior to the enrolment visit
i) Known immunocompromised status, including but not limited to, individuals who have undergone organ transplantation or who are positive for the human immunodeficiency virus
j) Malignancy within 5 years of the screening visit (with the exception of treated basal cell or treated squamous cell carcinoma of the skin)
5) Other Exclusion Criteria
a) Prisoners or subjects who are involuntarily incarcerated
b) Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
c) Replacement or chronic systemic corticosteroid therapy, defined as any dose of systemic corticosteroid taken for > 4 weeks within 3 months prior to Day -3 visit. NOTE: Topical or inhaled corticosteroids are allowed.
d) Any unstable endocrine, psychiatric, rheumatic disorders as judged by the Investigator.
e) Subject is, in the judgment of the Investigator, unlikely to comply with the protocol or has any severe concurrent medical or psychological condition that may affect the interpretation of efficacy or safety data.
f) Subject with any condition which, in the judgment of the Investigator, may render the subject unable to complete the study or which may pose a significant risk to the subject.
g) Subject is currently abusing alcohol or other drugs or has done so within the last 6 months.
h) Subject is a participating investigator, study coordinator, employee of an investigator or immediate family member of any of the aforementioned.
i) Administration of any other investigational drug within 30 days of planned enrolment to this study.
j) No clinical conditions or clinically significant abnormalities, in any laboratory value(s) collected after screening and prior to randomization which, in the Investigator’s judgment, should preclude entry into the treatment period
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary study variable of interest is as follows:
• reduction of intravenous insulin dose with glucose kept between 160 - 220 mg/dl 24 hours after oral administration of 10mg dapagliflozin
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The intravenous insulin dose will be calculated as total infused insulin dose from study drug administration to 24h postdose. The primary analysis will be an ANOVA model using intravenous insulin dose as response variable and treatment, sequence and period as fixed factor and subject within sequence as random factor. The difference between dapagliflozin and placebo will be estimated, together with 2-sided 95% confidence interval.
To get further information on the effect of baseline A1c on reduction of intravenous insulin dose a point estimate and 95% confidence intervals for the mean change in intravenous insulin dose (percent change) between dapagliflozin and placebo will be provided for each HbA1c group as supportive analysis.
|
|
E.5.2 | Secondary end point(s) |
The secondary study variables of interest are described below:
• effect of baseline A1c on insulin-dose lowering effect of 10mg dapagliflozin
• increase of urinary glucose excretion with blood glucose kept between 160 - 220 mg/dl 24 hours after oral administration of 10mg dapagliflozin
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
To assess the effect of baseline A1c on intravenous insulin dose an ANCOVA model will be applied using intravenous insulin dose as response variable, treatment, sequence and period as fixed factor, baseline A1c as covariate and subject within sequence as random factor. The main effect of baseline A1c will be reported as a statistical result from the model. In addition, the difference between dapagliflozin and placebo will be estimated, together with 2-sided 95% confidence interval.
The urinary glucose excretion will be analyzed using the same model as described for the primary endpoint.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
First trial with pediatric patients |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS (anticipated for December 2015) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |